Jeffrey Lin, MD
Critical Care Medicine · Boise, IDNPI 1891704169
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,735 of the $2,751 with a category attached, or 63.1%. 18 manufacturers reported payments, led by ZOLL Respicardia, Inc. at 41.9% of the total. Reporting peaked in 2022 at $1,259 and has fallen 77.0% since, to $289 in 2025.
Across 40 payments — averaging $68.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Respicardia, Inc.$1K
- Inspire Medical Systems, Inc.$354
- GSK$255
- Actelion Pharmaceuticals US, Inc.$166
- Boehringer Ingelheim$141
- Jazz Pharmaceuticals Inc.$135
- plus $546 from 12 others
What the payments were for
- Travel & lodging$98836%
- Food & beverage$1,73563%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Respicardia, Inc. | 2 | $1,153 |
| Inspire Medical Systems, Inc. | 6 | $354 |
| GSK | 6 | $255 |
| Actelion Pharmaceuticals US, Inc. | 4 | $166 |
| Boehringer Ingelheim | 3 | $141 |
| Jazz Pharmaceuticals Inc. | 1 | $135 |
| Insmed, Inc. | 1 | $125 |
| Harmony Biosciences LLC | 1 | $124 |
| Cook Medical LLC | 4 | $81 |
| AstraZeneca | 4 | $68 |
| Resmed Corp | 1 | $28 |
| Medtronic | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Philips North America LLC | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few critical care medicine providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 25 | $303,634 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $99,682 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $37,834 |
| Spiriva RespimatTiotropium Bromide | 20 | $16,145 |
| Advair HfaFluticasone Propion/Salmeterol | 37 | $15,803 |
| Bosentan | 12 | $14,934 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $10,248 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $8,231 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,536 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $6,148 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $4,781 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $3,646 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 110 | $3,315 |
| Qvar RedihalerBeclomethasone Dipropionate | 13 | $3,279 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 22 | $2,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $141 | $319,77945 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $255 | $121,597163 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $68 | $48,08267 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $166 | $14,93412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few critical care medicine providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other critical care medicine in Boise
- Anil PatelBoise$235
- Nirmal CharanBoise$201
- Paula CarvalhoBoise$157
- Ivan Martinez AvalosBoise$18
- Carley StringerLewiston$2K
- Lyudmila BurkartCoeur D Alene$2K
- Francis JohansenBlackfoot$1K
- Elizabeth SpaetzelCoeur D Alene$1K
- Juan LeonPocatello$474
- Pratik SahaIdaho Falls$254
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.